Featured Image
Why is it important?
This is the first randomized, placebo controlled trial to confirm the clinical benefit of augmentation therapy for emphysema caused by alpha-1 antitrypsin deficiency.
Perspectives
I'm hopeful that this trial will encourage physicians and their staff to screen patients for this treatable deficiency. I'm also hopeful that the RAPID trial will encourage health care systems to fund augmentation therapy if they do not already do so.
Kenneth Chapman
Asthma & Airway Centre, UHN
Read the Original
This page is a summary of: Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial, The Lancet, July 2015, Elsevier,
DOI: 10.1016/s0140-6736(15)60860-1.
You can read the full text:
Contributors
The following have contributed to this page
